Reexploring cytomegalovirus serology in allogeneic hematopoietic cell transplantation
Uloženo v:
| Název: | Reexploring cytomegalovirus serology in allogeneic hematopoietic cell transplantation |
|---|---|
| Autoři: | Royston, Lena, Neofytos, Dionysios |
| Zdroj: | Curr Opin Infect Dis |
| Informace o vydavateli: | Ovid Technologies (Wolters Kluwer Health), 2024. |
| Rok vydání: | 2024 |
| Témata: | Cytomegalovirus / immunology, Serologic Tests / methods, Immunoglobulin G / blood, Hematopoietic Stem Cell Transplantation / adverse effects, Hematopoietic Stem Cell Transplantation, Cytomegalovirus, DNA, Viral / blood, Antibodies, Viral, Cytomegalovirus Infections / prevention & control, Antibodies, Viral / blood, 03 medical and health sciences, Transplantation, Homologous / adverse effects, 0302 clinical medicine, Immunoglobulin G, Cytomegalovirus Infections, DNA, Viral, INFECTIONS OF THE IMMUNOCOMPROMISED HOST: Edited by Genovefa Papanicolaou and Dionysios Neofytos, Humans, Transplantation, Homologous, Serologic Tests, Cytomegalovirus Infections / immunology |
| Popis: | Purpose of review Discuss the recent evidence on cytomegalovirus (CMV) serology in allogeneic hematopoeic cell transplant (HCT) recipients. Recent findings Whereas the role CMV-specific cellular mediated immunity has recently emerged as an important factor of CMV DNAemia posttransplant, the value of CMV serology has remained unchanged through decades, associated with donor selection and posttransplant prophylactic and monitoring strategies. In this review, we describe and discuss the emerging reports on the association between the magnitude of pretransplant CMV immunoglobulin G (IgG) titer and the posttransplant incidence of CMV DNAemia, as CMV IgG titer could become an additional tool in CMV risk assessment in the future. Summary Pretransplant recipient CMV serology may have significant implications in posttransplant CMV reactivation in allogeneic HCT recipients. |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1473-6527 0951-7375 |
| DOI: | 10.1097/qco.0000000000001025 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/38861267 https://archive-ouverte.unige.ch/unige:185597 https://doi.org/10.1097/qco.0000000000001025 |
| Rights: | CC BY NC ND URL: http://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
| Přístupové číslo: | edsair.doi.dedup.....18f158d6edc3f8ba4a3841f77caaba88 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Purpose of review Discuss the recent evidence on cytomegalovirus (CMV) serology in allogeneic hematopoeic cell transplant (HCT) recipients. Recent findings Whereas the role CMV-specific cellular mediated immunity has recently emerged as an important factor of CMV DNAemia posttransplant, the value of CMV serology has remained unchanged through decades, associated with donor selection and posttransplant prophylactic and monitoring strategies. In this review, we describe and discuss the emerging reports on the association between the magnitude of pretransplant CMV immunoglobulin G (IgG) titer and the posttransplant incidence of CMV DNAemia, as CMV IgG titer could become an additional tool in CMV risk assessment in the future. Summary Pretransplant recipient CMV serology may have significant implications in posttransplant CMV reactivation in allogeneic HCT recipients. |
|---|---|
| ISSN: | 14736527 09517375 |
| DOI: | 10.1097/qco.0000000000001025 |